[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100527175":3},{"organization":4,"armGroups":7,"interventions":25,"overallOfficials":31,"centralContacts":40,"locations":50,"responsibleParty":72,"collaborators":31,"id":76,"slug":77,"hasResults":78,"nctId":79,"briefTitle":80,"officialTitle":81,"acronym":31,"eligibilityCriteria":82,"healthyVolunteers":78,"sex":83,"minAge":84,"maxAge":85,"enrollmentInfo":86,"targetDuration":31,"studyType":89,"phases":90,"briefSummary":92,"conditions":93,"keywords":97,"overallStatus":53,"whyStopped":31,"lastUpdateSubmitDate":100,"lastUpdatePostDateStruct":101,"startDateStruct":104,"completionDateStruct":106,"leadSponsor":108,"locationsCount":109},{"fullName":5,"class":6},"National Cancer Institute, Egypt","OTHER",[8,14,20],{"label":9,"type":10,"description":11,"interventionNames":12},"Standard of Care","ACTIVE_COMPARATOR","systemic and palliative treatment according to physician discretion",[13],"Other: Standard of Care",{"label":15,"type":16,"description":17,"interventionNames":18},"Metastases Directed Therapy","EXPERIMENTAL","SABR for all metastatic sites followed by systemic treatment for 6 months",[19],"Radiation: Stereotactic Ablative Radiation Therapy",{"label":21,"type":16,"description":22,"interventionNames":23},"Locoregional Treatment of the Primary","patients who respond to MDT and ST will be randomized to undergo loco-regional treatment or not",[24],"Procedure: Locoregional treatment",[26,32,37],{"type":27,"name":28,"description":29,"armGroupLabels":30,"otherNames":31},"RADIATION","Stereotactic Ablative Radiation Therapy","SABR to all metastatic lesions",[15],null,{"type":33,"name":34,"description":35,"armGroupLabels":36,"otherNames":31},"PROCEDURE","Locoregional treatment","mastectomy or BCS for the primary tumor",[21],{"type":6,"name":9,"description":38,"armGroupLabels":39,"otherNames":31},"Systemic treatment and palliative treatment",[9],[41,46],{"name":42,"role":43,"phone":44,"phoneExt":31,"email":45},"Rimoun R Boutrus, M.D.","CONTACT","+201061056900","rimoun.boutrus@nci.cu.edu.eg",{"name":47,"role":43,"phone":48,"phoneExt":31,"email":49},"Joseph S Nayrouz, M.D.","+201272148324","j_nayrouz@yahoo.com",[51],{"facility":52,"status":53,"city":54,"state":31,"zip":55,"country":56,"countryCode":57,"cosmosGeoPoint":58,"geoPoint":63,"contacts":64},"National Cancer Institute","RECRUITING","Cairo","11796","Egypt","EG",{"type":59,"coordinates":60},"Point",[61,62],31.24967,30.06263,{"lat":62,"lon":61},[65,68],{"name":66,"role":43,"phone":67,"phoneExt":31,"email":45},"Rimoun R Boutrus, M.D., Ph.D.","00201061056900",{"name":69,"role":43,"phone":70,"phoneExt":31,"email":71},"Medhat El Sebaie, M.D., Ph.D","00201221900822","melsebaie@gmail.com",{"type":73,"investigatorFullName":74,"investigatorTitle":75,"investigatorAffiliation":5,"oldNameTitle":31,"oldOrganization":31},"PRINCIPAL_INVESTIGATOR","Rimoun Ramsis Anis Boutrus","Assistant Professor, Radiation Oncology","100527175","metastases-directed-therapy-for-oligometastatic-breast-cancer-100527175",false,"NCT06144346","Metastases Directed Therapy for Oligometastatic Breast Cancer","Role of Metastases Directed Radiotherapy in Addition to Standard of Care Systemic Treatment in the Management of Extracranial Oligometastatic Breast Cancer","Inclusion Criteria:\n\n* Female patients aged 18 to 70 years.\n* Pathological evidence of breast cancer, any grade, any T stage.\n* Radiological (at least) evidence of metastatic activity with maximum number of 5 extracranial lesions.\n* Performance status ≤ 2\n* No pre-existing conditions that may prohibit radiotherapy.\n\nExclusion Criteria:\n\n•.Pregnant and lactating women.\n\n* Prior radiotherapy to affected site(s) in less than a year.\n* Active Connective tissue diseases (e.g Rheumatoid Arthritis).\n* Progression to widespread metastatic disease\n* Cases with brain metastasis","FEMALE","18 Years","70 Years",{"count":87,"type":88},150,"ESTIMATED","INTERVENTIONAL",[91],"NA","This is a phase III randomized study evaluating the benefit from adding metastases directed therapy and locoregional treatment of the primary in breast cancer patients diagnosed with de novo oligometastatic disease patients will be randomized to receive the standard of care (SOC) treatment vs. systemic treatment + Stereotactic Ablative Radiation Therapy. Responders will be randomized to either undergo loco-regional management of the primary tumor or not",[94,95,96],"Breast Cancer","Metastatic Cancer","Metastatic Breast Cancer",[98,99],"stereotactic radiation","oligometastatic breast cancer","2023-11-20",{"date":102,"type":103},"2023-11-22","ACTUAL",{"date":105,"type":103},"2023-09-20",{"date":107,"type":88},"2028-09-20",{"name":5,"class":6},1]